Magtrace for Sentinel Lymph Node Biopsy in Breast Cancer
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 184 (estimated)
- Sponsor
- Endomagnetics Ltd. · Industry
This trial is looking for women with breast cancer who are undergoing surgery. Participants will receive a treatment called Magtrace that helps in detecting lymph nodes and will be monitored for any skin color changes afterward.
You may be able to join if
- I am 18 years old or older.
- I am willing to give consent to participate.
- I am planning to have breast conserving surgery.
- I will have a sentinel lymph node biopsy with Magtrace.
You may not be able to join if
- I am pregnant or breastfeeding.
- I have had prior radiation treatment on the same breast.
- I have signs of advanced cancer or swollen lymph nodes.
- I received a Feraheme (ferumoxytol) injection in the last 6 months.
- I am allergic to iron or dextran compounds.
- I have iron overload disease.
- I have skin discoloration on my breast that might affect the study.
- I plan to get a tattoo on my breast after surgery.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on patients when it does occur using patient reported outcome measures.
Loading trial locations…